Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
BackgroundSemaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults. However, real-world data regarding its long-term gastrointestinal safety and tolerability in large sample population are incomplete. We evaluated semaglu...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2022-10-01
|
| 叢編: | Frontiers in Public Health |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fpubh.2022.996179/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|